Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity
© 2014 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd..
AIM: Psoriatic arthritis (PsA) is an inflammatory form of arthritis typically associated with psoriasis and/or psoriatic nail disease. Adipocytokines were once thought to influence development of (only) insulin resistance and diabetes mellitus. However, it is now clear that adipocytokines play important roles in development of the inflammation associated with either autoimmune or auto-inflammatory disorders. In the present study, we measured changes in the serum levels of adiponectin, resistin and visfatin, and the associations of such changes with the extent of disease activity and insulin resistance in PsA patients.
MATERIAL AND METHODS: A total of 67 subjects (28 with PsA and 39 healthy controls) without hypertension or diabetes mellitus were enrolled. Adiponectin, resistin and visfatin levels, and the extent of insulin resistance (assayed using the homeostasis model [HOMA-IR]), were measured in all subjects. Assessment of PsA disease activity was done with the Disease Activity Index for Psoriatic Arthritis (DAPSA).
RESULTS: Psoriatic arthritis patients had considerably higher serum levels of adiponectin, resistin and visfatin than did healthy controls (all P < 0.05). In the logistic regression analysis, the following variables may contribute to complex pathogenesis of PsA: adiponectin (P = 0.001, OR = 3.1, 95% CI = 1.6-6.0), resistin (P = 006, OR = 1.8, 95% CI = 1.2-2.9) and visfatin (P = 0.031, OR = 3.9, 95% CI = 1.1-13.9). In contrast, we have not detected any correlation between DAPSA and adipocytokine serum levels (P > 0.05).
CONCLUSION: There is no correlation between adipocytokines and disease activity. Although serum adiponectin, resistin and visfatin levels are higher in patients with PsA, pathophysiological significance of the result has to be evaluated with more extensive studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
International journal of rheumatic diseases - 19(2016), 7 vom: 22. Juli, Seite 672-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dikbas, Oguz [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.06.2017 Date Revised 20.03.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1756-185X.12444 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM241670101 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM241670101 | ||
| 003 | DE-627 | ||
| 005 | 20231224124744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1756-185X.12444 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0805.xml |
| 035 | |a (DE-627)NLM241670101 | ||
| 035 | |a (NLM)25196858 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dikbas, Oguz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2017 | ||
| 500 | |a Date Revised 20.03.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2014 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd. | ||
| 520 | |a AIM: Psoriatic arthritis (PsA) is an inflammatory form of arthritis typically associated with psoriasis and/or psoriatic nail disease. Adipocytokines were once thought to influence development of (only) insulin resistance and diabetes mellitus. However, it is now clear that adipocytokines play important roles in development of the inflammation associated with either autoimmune or auto-inflammatory disorders. In the present study, we measured changes in the serum levels of adiponectin, resistin and visfatin, and the associations of such changes with the extent of disease activity and insulin resistance in PsA patients | ||
| 520 | |a MATERIAL AND METHODS: A total of 67 subjects (28 with PsA and 39 healthy controls) without hypertension or diabetes mellitus were enrolled. Adiponectin, resistin and visfatin levels, and the extent of insulin resistance (assayed using the homeostasis model [HOMA-IR]), were measured in all subjects. Assessment of PsA disease activity was done with the Disease Activity Index for Psoriatic Arthritis (DAPSA) | ||
| 520 | |a RESULTS: Psoriatic arthritis patients had considerably higher serum levels of adiponectin, resistin and visfatin than did healthy controls (all P < 0.05). In the logistic regression analysis, the following variables may contribute to complex pathogenesis of PsA: adiponectin (P = 0.001, OR = 3.1, 95% CI = 1.6-6.0), resistin (P = 006, OR = 1.8, 95% CI = 1.2-2.9) and visfatin (P = 0.031, OR = 3.9, 95% CI = 1.1-13.9). In contrast, we have not detected any correlation between DAPSA and adipocytokine serum levels (P > 0.05) | ||
| 520 | |a CONCLUSION: There is no correlation between adipocytokines and disease activity. Although serum adiponectin, resistin and visfatin levels are higher in patients with PsA, pathophysiological significance of the result has to be evaluated with more extensive studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adiponectin | |
| 650 | 4 | |a insulin resistance | |
| 650 | 4 | |a psoriatic arthritis | |
| 650 | 4 | |a resistin | |
| 650 | 4 | |a visfatin | |
| 650 | 7 | |a ADIPOQ protein, human |2 NLM | |
| 650 | 7 | |a Adiponectin |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a RETN protein, human |2 NLM | |
| 650 | 7 | |a Resistin |2 NLM | |
| 650 | 7 | |a Nicotinamide Phosphoribosyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.4.2.12 |2 NLM | |
| 650 | 7 | |a nicotinamide phosphoribosyltransferase, human |2 NLM | |
| 650 | 7 | |a EC 2.4.2.12 |2 NLM | |
| 700 | 1 | |a Tosun, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Bes, Cemal |e verfasserin |4 aut | |
| 700 | 1 | |a Tonuk, Sukru Burak |e verfasserin |4 aut | |
| 700 | 1 | |a Aksehirli, Ozge Yilmaz |e verfasserin |4 aut | |
| 700 | 1 | |a Soy, Mehmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of rheumatic diseases |d 2009 |g 19(2016), 7 vom: 22. Juli, Seite 672-7 |w (DE-627)NLM197180566 |x 1756-185X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2016 |g number:7 |g day:22 |g month:07 |g pages:672-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1756-185X.12444 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2016 |e 7 |b 22 |c 07 |h 672-7 | ||